{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:36:01Z","timestamp":1761514561947,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.anndiagpath.2020.151519","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T11:50:12Z","timestamp":1586346612000},"page":"151519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["1p\/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma"],"prefix":"10.1016","volume":"46","author":[{"given":"Cyril","family":"Andrews","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Prayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"WHO classification of Tumours of the central nervous system","key":"10.1016\/j.anndiagpath.2020.151519_bb0005"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fonc.2019.00506","article-title":"Isocitrate dehydrogenase mutations in glioma: from basic discovery to therapeutic development","volume":"9","author":"Huag","year":"2019","journal-title":"Frontiers Oncol"},{"issue":"19","key":"10.1016\/j.anndiagpath.2020.151519_bb0030","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10014-011-0029-1","article-title":"Genetic profile of astrocytic and oligodendroglial gliomas","volume":"28","author":"Ohgaki","year":"2011","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12032-018-1119-2","article-title":"Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization","volume":"35","author":"Sim","year":"2018","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2020.151519_bb0045","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/nan.12031","article-title":"1p\/19q testing has no significance in the workup of glioblastomas","volume":"39","author":"Clark","year":"2013","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2020.151519_bb0050","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/PAI.0b013e3181a2c6a4","article-title":"Chromosome 1p and 19q deletions in glioblastoma multiforme","volume":"17","author":"Kaneshiro","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2020.151519_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10014-006-0209-6","article-title":"FISH 1p\/19q deletion\/imbalance for molecular subclassification of glioblastoma","volume":"24","author":"Nagasaka","year":"2007","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s10014-012-0107-z","article-title":"Molecular characteristics of glioblastoma with 1p\/19q co-deletion","volume":"29","author":"Mizoguchi","year":"2012","journal-title":"Brain Tumor Pathol"},{"issue":"26","key":"10.1016\/j.anndiagpath.2020.151519_bb0065","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.anndiagpath.2020.151519_bb0070","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.4103\/0028-3886.246275","article-title":"Molecular profile of tumors with oligodendroglial morphology: clinical relevance","volume":"66","author":"Geevar","year":"2018","journal-title":"Neurol India"},{"issue":"2","key":"10.1016\/j.anndiagpath.2020.151519_bb0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/his.12927","article-title":"Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas","volume":"69","author":"Ikemura","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00401-012-1031-3","article-title":"Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1\/IDH2 and TP53 mutations","volume":"124","author":"Liu","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-013-1156-z","article-title":"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis","volume":"126","author":"Wiestler","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.18632\/oncotarget.588","article-title":"Frequent ATRX, CIC, and FUBPa mutations refine the classification of malignant gliomas","volume":"3","author":"Jiao","year":"2012","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.anndiagpath.2020.151519_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnen\/nlv009","article-title":"Diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas","volume":"75","author":"Tanboon","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2020.151519_bb0100","first-page":"228","article-title":"p53 protein alterations in adult astrocytic tumors and oligodendrogliomas","volume":"52","author":"Nayak","year":"2004","journal-title":"Neurol India"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1215\/S1522851798000179","article-title":"Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression","volume":"1","author":"Nozaki","year":"1999","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.anndiagpath.2020.151519_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF01600211","article-title":"Expression of the epidermal growth receptor in astrocytic tumours is specifically associated with glioblastoma multiforme","volume":"420","author":"Agosti","year":"1992","journal-title":"Virchows Archiv A Pahtol Anat"},{"issue":"4","key":"10.1016\/j.anndiagpath.2020.151519_bb0115","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0028-3886.44827","article-title":"Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas","volume":"56","author":"Maiti","year":"2008","journal-title":"Neurol India"},{"issue":"9","key":"10.1016\/j.anndiagpath.2020.151519_bb0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1593\/neo.10688","article-title":"Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance","volume":"12","author":"Hatanpaa","year":"2010","journal-title":"Neoplasia"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420300605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420300605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:32:07Z","timestamp":1761078727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913420300605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":24,"alternative-id":["S1092913420300605"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151519","relation":{},"ISSN":["1092-9134"],"issn-type":[{"type":"print","value":"1092-9134"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1p\/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151519"}}